Reported Earnings • Aug 15
First quarter 2027 earnings released: ₹0.61 loss per share (vs ₹3.25 profit in 1Q 2026) First quarter 2027 results: ₹0.61 loss per share (down from ₹3.25 profit in 1Q 2026). Revenue: ₹231.4m (down 9.3% from 1Q 2026). Net loss: ₹17.9m (down 119% from profit in 1Q 2026). Over the last 3 years on average, earnings per share has increased by 95% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Announcement • Aug 10
Brooks Laboratories Limited, Annual General Meeting, Sep 03, 2026 Brooks Laboratories Limited, Annual General Meeting, Sep 03, 2026, at 09:00 Indian Standard Time. Announcement • Aug 06
Brooks Laboratories Limited to Report Q1, 2027 Results on Aug 13, 2026 Brooks Laboratories Limited announced that they will report Q1, 2027 results on Aug 13, 2026 Announcement • Jul 17
Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026 Brooks Laboratories Limited had appointed Mr. Rajesh Mahajan as President Trading and Senior Management Personnel of the Company with effect from July 17, 2026. Mr. Rajesh Mahajan holds a Bachelor's Degree in Biology and an MBA in Marketing. He has over 20+ years of experience in the pharmaceutical industry, with extensive expertise in pharmaceutical formulations and manufacturing operations. He has been instrumental in the growth of Brooks Laboratories Limited's formulation business and also played a key role in planning and executing new projects and business development initiatives. Announcement • Jun 20
Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited (NSEI:BROOKS) for INR 1.1 billion. Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited (NSEI:BROOKS) for INR 1.1 billion on June 19, 2026. A cash consideration of INR 1.06 billion will be paid by Steriscience Specialties Private Limited.Upon completion, Steriscience Specialties Private Limited will own 67.33% stake in Brooks Steriscience Limited.
The transaction is subject to approval of merger agreement by target board and approval by regulatory board / committee. Reported Earnings • May 31
Full year 2026 earnings released: EPS: ₹8.35 (vs ₹3.72 loss in FY 2025) Full year 2026 results: EPS: ₹8.35 (up from ₹3.72 loss in FY 2025). Revenue: ₹869.1m (up 5.3% from FY 2025). Net income: ₹245.8m (up ₹345.5m from FY 2025). Profit margin: 28% (up from net loss in FY 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Announcement • May 22
Brooks Laboratories Limited to Report Q4, 2026 Results on May 29, 2026 Brooks Laboratories Limited announced that they will report Q4, 2026 results at 4:00 PM, Indian Standard Time on May 29, 2026 Valuation Update With 7 Day Price Move • May 22
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹53.73, the stock trades at a trailing P/E ratio of 7.3x. Average trailing P/E is 33x in the Life Sciences industry in India. Total loss to shareholders of 11% over the past three years. Valuation Update With 7 Day Price Move • May 01
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹55.98, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 33x in the Life Sciences industry in India. Total loss to shareholders of 12% over the past three years. Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment improves as stock rises 34% After last week's 34% share price gain to ₹71.57, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 30x in the Life Sciences industry in India. Total returns to shareholders of 6.3% over the past three years. Buy Or Sell Opportunity • Mar 23
Now 30% undervalued after recent price drop Over the last 90 days, the stock has fallen 50% to ₹46.03. The fair value is estimated to be ₹65.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Mar 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.1% average weekly change). Minor Risk Market cap is less than US$100m (₹1.63b market cap, or US$17.7m). Valuation Update With 7 Day Price Move • Feb 13
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹75.81, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 30x in the Life Sciences industry in India. Total loss to shareholders of 22% over the past three years. Reported Earnings • Feb 07
Third quarter 2026 earnings released: EPS: ₹1.87 (vs ₹1.75 loss in 3Q 2025) Third quarter 2026 results: EPS: ₹1.87 (up from ₹1.75 loss in 3Q 2025). Revenue: ₹166.9m (down 57% from 3Q 2025). Net income: ₹55.0m (up ₹100.7m from 3Q 2025). Profit margin: 33% (up from net loss in 3Q 2025). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • Jan 30
Brooks Laboratories Limited to Report Q3, 2026 Results on Feb 06, 2026 Brooks Laboratories Limited announced that they will report Q3, 2026 results on Feb 06, 2026 New Risk • Dec 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (₹2.08b market cap, or US$23.1m). Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹77.77, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 33x in the Life Sciences industry in India. Total loss to shareholders of 28% over the past three years. Reported Earnings • Nov 16
Second quarter 2026 earnings released: EPS: ₹2.71 (vs ₹1.51 loss in 2Q 2025) Second quarter 2026 results: EPS: ₹2.71 (up from ₹1.51 loss in 2Q 2025). Revenue: ₹238.4m (up 15% from 2Q 2025). Net income: ₹79.8m (up ₹119.4m from 2Q 2025). Profit margin: 34% (up from net loss in 2Q 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Announcement • Nov 08
Brooks Laboratories Limited to Report Q2, 2026 Results on Nov 14, 2025 Brooks Laboratories Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Announcement • Sep 03
Brooks Laboratories Limited, Annual General Meeting, Sep 26, 2025 Brooks Laboratories Limited, Annual General Meeting, Sep 26, 2025, at 09:00 Indian Standard Time. Reported Earnings • Aug 14
First quarter 2026 earnings released: EPS: ₹3.25 (vs ₹0.94 loss in 1Q 2025) First quarter 2026 results: EPS: ₹3.25 (up from ₹0.94 loss in 1Q 2025). Revenue: ₹257.3m (up 44% from 1Q 2025). Net income: ₹95.8m (up ₹120.0m from 1Q 2025). Profit margin: 37% (up from net loss in 1Q 2025). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth. Announcement • Aug 09
Brooks Laboratories Limited to Report Q1, 2026 Results on Aug 13, 2025 Brooks Laboratories Limited announced that they will report Q1, 2026 results on Aug 13, 2025 Reported Earnings • May 29
Full year 2025 earnings released: ₹3.72 loss per share (vs ₹7.65 loss in FY 2024) Full year 2025 results: ₹3.72 loss per share (improved from ₹7.65 loss in FY 2024). Revenue: ₹834.4m (up 5.0% from FY 2024). Net loss: ₹99.7m (loss narrowed 49% from FY 2024). Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 18% per year. Announcement • May 23
Brooks Laboratories Limited to Report Q4, 2025 Results on May 28, 2025 Brooks Laboratories Limited announced that they will report Q4, 2025 results on May 28, 2025 New Risk • Mar 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹3.13b market cap, or US$35.8m). Reported Earnings • Feb 15
Third quarter 2025 earnings released: ₹1.75 loss per share (vs ₹1.51 loss in 3Q 2024) Third quarter 2025 results: ₹1.75 loss per share (further deteriorated from ₹1.51 loss in 3Q 2024). Revenue: ₹384.5m (up 77% from 3Q 2024). Net loss: ₹45.7m (loss widened 18% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 15% per year. Announcement • Feb 10
Brooks Laboratories Limited to Report Q3, 2025 Results on Feb 13, 2025 Brooks Laboratories Limited announced that they will report Q3, 2025 results on Feb 13, 2025 Announcement • Dec 26
Brooks Laboratories Limited Appoints Ms. Krutika Mohan Rane as Company Secretary & Compliance Officer, Effective 26 December 2024 Brooks Laboratories Limited approved the appointment of Ms. Krutika Mohan Rane, Associate Member of the Institute of Company Secretaries of India, having membership no. ACS-66310, as Company Secretary & Compliance Officer of the company in terms of provisions of Section 203 of the Companies Act, 2013 and Rule made thereunder and Regulation 6 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 effective from 26 December 2024. Ms. Krutika Mohan Rane Is an Associate Member of the Institute of Company Secretaries of India (Icsi), with Membership Number Acs-66310. She Holds the Necessary Qualifications and Skills in Secretarial Compliance. Ms. Rane Is Also A Law Graduate and Has Gained Practical Experience in Corporate Law and Listing Regulations through Various Assignments. Announcement • Dec 13
Brooks Laboratories Limited announced that it expects to receive INR 750 million in funding BROOKS LABORATORIES LIMITED announced a private placement to issue common shares for the gross proceeds of INR 750,000,000 on December 11, 2024. The transaction has been approved by shareholders of company. Recent Insider Transactions • Nov 19
Insider recently sold ₹66m worth of stock On the 14th of November, Aryan Mahajan sold around 480k shares on-market at roughly ₹137 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹90m more than they bought in the last 12 months. Reported Earnings • Nov 10
Second quarter 2025 earnings released: ₹1.51 loss per share (vs ₹0.64 loss in 2Q 2024) Second quarter 2025 results: ₹1.51 loss per share (further deteriorated from ₹0.64 loss in 2Q 2024). Revenue: ₹209.9m (down 14% from 2Q 2024). Net loss: ₹39.6m (loss widened 142% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • Nov 07
Brooks Laboratories Limited to Report Q2, 2025 Results on Nov 09, 2024 Brooks Laboratories Limited announced that they will report Q2, 2025 results on Nov 09, 2024 Announcement • Oct 21
Brooks Laboratories Limited Announces Cessation of Sonia Gupta as Independent Director Brooks Laboratories Limited announced that Sonia Gupta has completed her second and final term of five consecutive years as an Independent Director of the Company on 28th September, 2024 and consequently ceased to be an Independent Director of the Company effective from 29th September, 2024. Announcement • Sep 20
Brooks Laboratories Limited Announces Board Appointments Brooks Laboratories Limited at its AGM held on September 19, 2024 approved appointment of Mr. Lalit Mahajan, Dr. Usha Singh and Mr. Manav Mahajan as Independent Directors. Mr. Lalit Mahajan has been appointed as an Independent Director on the Board of the Company for a term of 5 consecutive years with effect from August 7, 2024, with approval of shareholders at the Annual general meeting of the Company. Mr. Lalit Mahajan, aged 59, has a master's Degree in Arts. He has vast experience of 20 years in marketing. His association brings years of professional experience to facilitate developing and implementing marketing strategy and analyze the market and competitors of the Organization. Dr. Usha Singh has been appointed as an Additional Independent Director on the Board of the Company for a term of 5 consecutive years with effect from August 7, 2024, with approval of shareholders at the Annual general meeting of the Company. Dr. Usha Singh, aged 56, has a M.Sc. (Physics), Ph.D. (Renewable Energy). She has vast experience in experimental Science. She has more than ten research papers of internationally published. Mr. Manav Mahajan has been appointed as an Additional Independent Director on the Board of the Company for a term of 5 consecutive years with effect from September 29, 2024, with approval of shareholders at the Annual general meeting of the Company. Mr. Manav Mahajan aged 48, has a degree in Bachelor's of Technology (Production Engineering) from Punjab Engineering College and has a vast experience in manufacturing and export of various commodities all over the world. New Risk • Sep 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₹101m free cash flow). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹3.75b market cap, or US$44.7m). Board Change • Sep 03
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Independent Director Sonia Gupta is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Aug 28
Brooks Laboratories Limited, Annual General Meeting, Sep 19, 2024 Brooks Laboratories Limited, Annual General Meeting, Sep 19, 2024, at 09:00 Indian Standard Time. Reported Earnings • Aug 15
First quarter 2025 earnings released: ₹0.94 loss per share (vs ₹1.81 loss in 1Q 2024) First quarter 2025 results: ₹0.94 loss per share (improved from ₹1.81 loss in 1Q 2024). Revenue: ₹180.0m (up 15% from 1Q 2024). Net loss: ₹24.1m (loss narrowed 46% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Aug 06
Brooks Laboratories Limited to Report Q1, 2025 Results on Aug 14, 2024 Brooks Laboratories Limited announced that they will report Q1, 2025 results on Aug 14, 2024 New Risk • Jun 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹101m free cash flow). Earnings have declined by 1.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (6.3% increase in shares outstanding). Market cap is less than US$100m (₹2.11b market cap, or US$25.3m). Reported Earnings • May 21
Full year 2024 earnings released: ₹7.67 loss per share (vs ₹8.46 loss in FY 2023) Full year 2024 results: ₹7.67 loss per share (improved from ₹8.46 loss in FY 2023). Revenue: ₹804.4m (up 27% from FY 2023). Net loss: ₹195.9m (loss narrowed 6.3% from FY 2023). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 01
Third quarter 2024 earnings released: ₹1.51 loss per share (vs ₹2.03 loss in 3Q 2023) Third quarter 2024 results: ₹1.51 loss per share (improved from ₹2.03 loss in 3Q 2023). Revenue: ₹219.0m (up 43% from 3Q 2023). Net loss: ₹38.8m (loss narrowed 23% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jan 24
Brooks Laboratories Limited to Report Q3, 2024 Results on Jan 31, 2024 Brooks Laboratories Limited announced that they will report Q3, 2024 results on Jan 31, 2024 Reported Earnings • Nov 10
Second quarter 2024 earnings released: ₹0.64 loss per share (vs ₹3.19 loss in 2Q 2023) Second quarter 2024 results: ₹0.64 loss per share (improved from ₹3.19 loss in 2Q 2023). Revenue: ₹244.1m (up 35% from 2Q 2023). Net loss: ₹16.4m (loss narrowed 65% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Sep 22
Brooks Laboratories Limited Announces Director Appointments Brooks Laboratories Limited announced that at its AGM held on September 21, 2023, Dr. Durga Shankar Maity has been appointed as Whole Time Director of the company for a term of 5 years effective from July 7, 2023; Mr. Bhushan Singh Rana has been appointed as a Whole-time Director of the Company for a term of 5 years effective from August 23, 2023. Announcement • Sep 01
Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023 Brooks Laboratories Limited, Annual General Meeting, Sep 21, 2023, at 09:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements of the Company for the financial year ended 31 March 2023 and the Report of directors and Auditors thereon; to reappoint Mr. Jitendra Pratap Singh, who retires by rotation, and being eligible, offers himself for reappointment; to ratify the remuneration of the Cost Auditors; to Approval for Related Party Transactions; to consider the appointment of Dr. Durga Shankar Maity as Whole Time Director of the Company; to consider the appointment of Mr. Bhushan Singh Rana as Whole Time Director of the Company; and to discuss other matters. New Risk • Aug 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹150m free cash flow). Earnings have declined by 11% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (6.3% increase in shares outstanding). Market cap is less than US$100m (₹2.47b market cap, or US$29.9m). Reported Earnings • Aug 11
First quarter 2024 earnings released: ₹1.81 loss per share (vs ₹3.80 loss in 1Q 2023) First quarter 2024 results: ₹1.81 loss per share (improved from ₹3.80 loss in 1Q 2023). Revenue: ₹157.6m (down 8.0% from 1Q 2023). Net loss: ₹44.7m (loss narrowed 35% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 37% per year, which means it is well ahead of earnings. Announcement • Aug 03
Brooks Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023 Brooks Laboratories Limited announced that they will report Q1, 2024 results on Aug 10, 2023 Reported Earnings • Feb 15
Third quarter 2023 earnings released: ₹2.03 loss per share (vs ₹3.14 loss in 3Q 2022) Third quarter 2023 results: ₹2.03 loss per share (improved from ₹3.14 loss in 3Q 2022). Revenue: ₹154.0m (down 21% from 3Q 2022). Net loss: ₹50.2m (loss narrowed 35% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 55% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 11
First quarter 2023 earnings released: ₹3.80 loss per share (vs ₹0.47 loss in 1Q 2022) First quarter 2023 results: ₹3.80 loss per share (down from ₹0.47 loss in 1Q 2022). Revenue: ₹171.6m (down 23% from 1Q 2022). Net loss: ₹69.0m (loss widened ₹57.6m from 1Q 2022). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 28% per year, which means it is well ahead of earnings. Reported Earnings • Jun 04
Full year 2022 earnings released: ₹7.82 loss per share (vs ₹7.84 loss in FY 2021) Full year 2022 results: ₹7.82 loss per share (up from ₹7.84 loss in FY 2021). Revenue: ₹919.9m (up 18% from FY 2021). Net loss: ₹161.9m (loss narrowed 17% from FY 2021). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 16% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Feb 16
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: ₹3.14 loss per share (down from ₹1.03 loss in 3Q 2021). Revenue: ₹193.8m (down 7.4% from 3Q 2021). Net loss: ₹77.5m (loss widened 204% from 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings. Reported Earnings • Nov 13
Second quarter 2022 earnings released: ₹1.97 loss per share (vs ₹1.35 profit in 2Q 2021) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2022 results: Revenue: ₹215.7m (down 26% from 2Q 2021). Net loss: ₹48.3m (down 244% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings. Board Change • Sep 15
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Sonia Gupta was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Executive Departure • Sep 13
Technical Director & Whole Time Director Suresh Garg has left the company On the 3rd of September, Suresh Garg's tenure as Technical Director & Whole Time Director ended after 2.0 years in the role. As of June 2021, Suresh still personally held only 410.00 shares (₹40k worth at the time). Suresh is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.08 years. Board Change • Sep 13
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Independent Director Sonia Gupta was the last director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Jul 06
Full year 2021 earnings released: ₹7.76 loss per share (vs ₹13.84 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: ₹772.5m (up 11% from FY 2020). Net loss: ₹193.8m (loss narrowed 21% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Reported Earnings • Feb 12
Third quarter 2021 earnings released: ₹1.03 loss per share (vs ₹1.67 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: ₹209.6m (up 5.4% from 3Q 2020). Net loss: ₹25.6m (loss narrowed 9.0% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 15% per year. Is New 90 Day High Low • Feb 12
New 90-day low: ₹58.60 The company is down 6.0% from its price of ₹62.25 on 14 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 9.0% over the same period. Is New 90 Day High Low • Jan 04
New 90-day high: ₹73.20 The company is up 7.0% from its price of ₹68.25 on 06 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 20% over the same period. Is New 90 Day High Low • Dec 02
New 90-day high: ₹71.75 The company is up 79% from its price of ₹40.10 on 03 September 2020. The Indian market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 10.0% over the same period. Is New 90 Day High Low • Oct 08
New 90-day high: ₹68.75 The company is up 134% from its price of ₹29.35 on 10 July 2020. The Indian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 42% over the same period. Reported Earnings • Sep 18
First quarter earnings released Over the last 12 months the company has reported total losses of ₹235.3m, with losses widening by 59% from the prior year. Total revenue was ₹653.3m over the last 12 months, up 6.8% from the prior year. 
